BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31397619)

  • 1. Harnessing the Biologics and Biosimilars Collective Intelligence Consortium to Evaluate Patterns of Care.
    McMahill-Walraven CN; Kent DJ; Panozzo CA; Pawloski PA; Haynes K; Marshall J; Brown J; Eichelberger B; Lockhart CM
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1156-1161. PubMed ID: 31397619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Descriptive Analysis of Long- and Intermediate-Acting Insulin and Key Safety Outcomes in Adults with Type 2 Diabetes Mellitus.
    Kent DJ; McMahill-Walraven CN; Panozzo CA; Pawloski PA; Haynes K; Marshall J; Brown J; Eichelberger B; Lockhart CM
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1162-1171. PubMed ID: 31405345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance.
    Zhang J; Sridhar G; Barr CE; Eichelberger B; Lockhart CM; Marshall J; Clewell J; Accortt NA; Curtis JR; Holmes C; McMahill-Walraven CN; Brown JS; Haynes K
    J Manag Care Spec Pharm; 2020 Apr; 26(4):417-490. PubMed ID: 32223608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated With High-Neutropenia Risk Chemotherapy.
    Pawloski PA; McDermott CL; Marshall JH; Pindolia V; Lockhart CM; Panozzo CA; Brown JS; Eichelberger B
    J Natl Compr Canc Netw; 2021 Aug; ():. PubMed ID: 34399406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States.
    Rai A; Nam YH; Mendelsohn AB; Marshall J; McDermott CL; Toh S; Lockhart CM
    J Manag Care Spec Pharm; 2023 Jul; 29(7):842-847. PubMed ID: 37404073
    [No Abstract]   [Full Text] [Related]  

  • 6. Capture of biologic and biosimilar dispensings in a consortium of U.S.-based claims databases: Utilization of national drug codes and Healthcare Common Procedure Coding System modifiers in medical claims.
    Zhang J; Haynes K; Mendelsohn AB; Marshall J; Barr CE; McDermott C; Brown J; Kline A; Kenney J; King KJ; Holmes C; Yeung K; Barron J; Yun H; Lockhart CM
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):778-785. PubMed ID: 31802568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilizing data consortia to monitor safety and effectiveness of biosimilars and their innovator products.
    ; Baldziki M; Brown J; Chan H; Cheetham TC; Conn T; Daniel GW; Hendrickson M; Hilbrich L; Johnson A; Miller SB; Moore T; Motheral B; Priddy SA; Raebel MA; Randhawa G; Surratt P; Walraven C; White TJ; Bruns K; Carden MJ; Dragovich C; Eichelberger B; Rosato E; Sega T
    J Manag Care Spec Pharm; 2015 Jan; 21(1):23-34. PubMed ID: 25562770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN.
    Dolinar R; Lavernia F; Edelman S
    Endocr Pract; 2018 Feb; 24(2):195-204. PubMed ID: 29466056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
    Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
    J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
    Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
    [No Abstract]   [Full Text] [Related]  

  • 11. Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars.
    Desai RJ; Kim SC; Curtis JR; Bosco JLF; Eichelberger B; Barr CE; Lockhart CM; Bradbury BD; Clewell J; Cohen HP; Gagne JJ;
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):757-769. PubMed ID: 31298463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?
    Hung A; Vu Q; Mostovoy L
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1234-1244. PubMed ID: 29172975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping from the International Classification of Diseases (ICD) 9th to 10th Revision for Research in Biologics and Biosimilars Using Administrative Healthcare Data.
    He M; Santiago Ortiz AJ; Marshall J; Mendelsohn AB; Curtis JR; Barr CE; Lockhart CM; Kim SC
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):770-777. PubMed ID: 31854053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMCP Partnership Forum: Biosimilars--Ready, Set, Launch.
    J Manag Care Spec Pharm; 2016 Apr; 22(4):434-40. PubMed ID: 27023697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2017 Feb; 19(S1):S42-S58. PubMed ID: 28192016
    [No Abstract]   [Full Text] [Related]  

  • 17. AMCP Partnership Forum: Biosimilars-policy, practice, and postmarketing surveillance to support treatment and coverage decisions.
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1503-1508. PubMed ID: 34459234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars: Implications for health-system pharmacists.
    Lucio SD; Stevenson JG; Hoffman JM
    Am J Health Syst Pharm; 2013 Nov; 70(22):2004-17. PubMed ID: 24173009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacovigilance of Biologics in a Multisource Environment.
    Sagi S; Cohen HP; Woollett GR
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1249-1254. PubMed ID: 29172979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.